Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)
3.02 x 2 3.08 x 12
Post-market by (Cboe BZX)
3.02 -0.19 (-5.92%) 03/28/25 [NASDAQ]
3.02 x 2 3.08 x 12
Post-market 3.08 +0.06 (+1.99%) 18:21 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.98
Day High
3.20
Open 3.19
Previous Close 3.21 3.21
Volume 1,129,400 1,129,400
Avg Vol 1,359,700 1,359,700
Stochastic %K 69.21% 69.21%
Weighted Alpha -31.26 -31.26
5-Day Change -0.19 (-5.92%) -0.19 (-5.92%)
52-Week Range 2.24 - 5.80 2.24 - 5.80
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 298,590
  • Shares Outstanding, K 98,871
  • Annual Sales, $ 57,560 K
  • Annual Income, $ -44,140 K
  • EBIT $ -31 M
  • EBITDA $ -19 M
  • 60-Month Beta 2.76
  • Price/Sales 5.51
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 118.14% ( +12.99%)
  • Historical Volatility 71.78%
  • IV Percentile 54%
  • IV Rank 17.81%
  • IV High 474.07% on 03/10/25
  • IV Low 41.00% on 08/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,172
  • Volume Avg (30-Day) 490
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 15,571
  • Open Int (30-Day) 17,056

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 4
  • High Estimate -0.16
  • Low Estimate -0.17
  • Prior Year -0.17
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.45 +23.27%
on 03/06/25
Period Open: 2.80
3.39 -10.91%
on 03/24/25
+0.22 (+7.86%)
since 02/28/25
3-Month
2.45 +23.27%
on 03/06/25
Period Open: 3.52
3.79 -20.32%
on 01/02/25
-0.50 (-14.20%)
since 12/27/24
52-Week
2.24 +34.82%
on 06/26/24
Period Open: 4.26
5.80 -47.93%
on 10/30/24
-1.24 (-29.11%)
since 03/28/24

Most Recent Stories

More News
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings

Stocktwits users are viewing the company's cash position, expectations for a late 2026 Anaphylm launch, and an upcoming trial as positive signals.

AQST : 3.02 (-5.92%)
Aquestive Therapeutics: Q4 Earnings Snapshot

Aquestive Therapeutics: Q4 Earnings Snapshot

AQST : 3.02 (-5.92%)
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

AQST : 3.02 (-5.92%)
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

AQST : 3.02 (-5.92%)
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

AQST : 3.02 (-5.92%)
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

AQST : 3.02 (-5.92%)
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

AQST : 3.02 (-5.92%)
How Advanced Drug Delivery is Revolutionizing Global Healthcare in 2025

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – How we deal with future spikes in disease cases and potential global pandemics is evolving rapidly. Not only is the...

BVAXF : 0.0388 (-2.76%)
SVRA : 2.91 (+4.68%)
BIOV.CN : 0.0500 (-9.09%)
TMO : 500.16 (-2.25%)
VERV : 5.22 (-1.14%)
AQST : 3.02 (-5.92%)
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

AQST : 3.02 (-5.92%)
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

AQST : 3.02 (-5.92%)

Business Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 3.38
2nd Resistance Point 3.29
1st Resistance Point 3.15
Last Price 3.02
1st Support Level 2.93
2nd Support Level 2.84
3rd Support Level 2.70

See More

52-Week High 5.80
Fibonacci 61.8% 4.44
Fibonacci 50% 4.02
Fibonacci 38.2% 3.60
Last Price 3.02
52-Week Low 2.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies